Scholarlink

Background <p>Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rare and highly aggressive malignancy with poor prognosis and no established standard therapy. This study aimed to map the research landscape of SMARCA4-UT through bibliometric analysis to guide clinical decision-making and research prioritization.</p> Methods <p>Publications on thoracic SMARCA4-UT were retrieved from the Web of Science Core Collection and Scopus from 2000 to 2025. After screening, 132 articles and reviews were included. Bibliometrix and CiteSpace were used to analyze publication trends, geographic and institutional distribution, author productivity, collaboration networks, keyword evolution, thematic structure, and highly cited articles.</p> Results <p>SMARCA4-UT research expanded rapidly, with 31.95% annual growth rate and 32.25 average citations per article, reflecting rising academic impact. China (28.8%) and Japan (23.5%) led global output, forming a China–US dual-core collaboration network. Mechanistic studies on the SWI/SNF complex and BRG1 are mature, while clinical and therapeutic research remains underdeveloped. Temporal analysis revealed a shift toward diagnostic standardization after the 2021 WHO classification.</p> Conclusions <p>SMARCA4-UT research is in a rapid growth phase, with a substantial gap between mechanistic advances and clinical translation. Immunochemotherapy is the current first-line backbone, while targeted and combinatorial strategies remain exploratory. These findings provide evidence-based guidance for clinical practice and research design, highlighting the urgent need for biomarker-driven therapy and large-scale international collaboration to improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bibliometric analysis and knowledge mapping of thoracic SMARCA4-deficient undifferentiated tumor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月24日

查看全文
  • Yujun Lin,
  • Di Wu,
  • Lujing Jiang,
  • Qin Shi

摘要

Background

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rare and highly aggressive malignancy with poor prognosis and no established standard therapy. This study aimed to map the research landscape of SMARCA4-UT through bibliometric analysis to guide clinical decision-making and research prioritization.

Methods

Publications on thoracic SMARCA4-UT were retrieved from the Web of Science Core Collection and Scopus from 2000 to 2025. After screening, 132 articles and reviews were included. Bibliometrix and CiteSpace were used to analyze publication trends, geographic and institutional distribution, author productivity, collaboration networks, keyword evolution, thematic structure, and highly cited articles.

Results

SMARCA4-UT research expanded rapidly, with 31.95% annual growth rate and 32.25 average citations per article, reflecting rising academic impact. China (28.8%) and Japan (23.5%) led global output, forming a China–US dual-core collaboration network. Mechanistic studies on the SWI/SNF complex and BRG1 are mature, while clinical and therapeutic research remains underdeveloped. Temporal analysis revealed a shift toward diagnostic standardization after the 2021 WHO classification.

Conclusions

SMARCA4-UT research is in a rapid growth phase, with a substantial gap between mechanistic advances and clinical translation. Immunochemotherapy is the current first-line backbone, while targeted and combinatorial strategies remain exploratory. These findings provide evidence-based guidance for clinical practice and research design, highlighting the urgent need for biomarker-driven therapy and large-scale international collaboration to improve patient outcomes.